PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 417 (xsd:integer)
nif:isString
  • Finally, the “dual target therapy” with perifosine and low dose of sorafenib in combination, by coupling the effects of sorafenib on PTEN and Akt dephosphorylation, with that induced by perifosine on CB dephosphorylation and activation, improves the sorafenib anti-tumor effects and potentially reduce the side-effects, thus providing a rationale for the use in clinical trials in patients suffering from advanced BC.
rdf:type